Acetazolamide for Treatment Resistant Schizophrenia
This is a double blind adjunctive randomized controlled trial for schizophrenia using acetazolamide.
| Condition(s) | Schizophrenia, Schizo Affective Disorder |
|---|---|
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Study type | Interventional |
| Summary | This is a double blind adjunctive randomized controlled trial for schizophrenia using acetazolamide. |
| Who can participate | Inclusion Criteria: * Written informed consent. * Both genders, ages 18-55 years (older patients may not tolerate high ACZ dose). * PANSS total score \> 60 and Score \> 4 on one or more items of the 'positive' syndrome items (P1-P7), following treatment at therapeutic doses for 6 weeks with different APDs on 2 occasions. * Stable dose of antipsychotic drug (APD) for \> 1 month, continued throughout the study. * Not participating in another randomized controlled clinical trial (RCT). Exclusion Criteria: * Substance abuse in the past month/dependence past 6 months with the exception of methadone prescribed for opiate withdrawal. * History or current medical/neurological illnesses that may lead to unstable course, e.g., epilepsy. * Pregnancy. * Acetazolamide (ACZ) contraindications: hypersens |
| Ages | 18 Years to 55 Years |
| Sex | All |
| Lead sponsor | Vishwajit Nimgaonkar, MD PhD |
| Locations | Pittsburgh, Pennsylvania, United States; Bangalore, India |
| Start date | 2022-02-01 |
| NCT ID | NCT04887792 |
| Official listing | https://clinicaltrials.gov/study/NCT04887792 |